ReviewClinics in laboratory medicine2022
The Successes and Challenges of SARS-CoV-2 Molecular Testing in the United States.
Review in Clinics in laboratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- A train-and-assist device that upskills novices to strengthen the workforce and expand diagnostic access.PNAS nexus · 2026Article
- Diagnostic Concordance of Two- and Three-Gene SARS-CoV-2 Molecular Assays in Cameroon: Implications for Efficient Pandemic Response in Low- and Middle-Income Countries.Journal of clinical laboratory analysis · 2026Article
- Review
- Coupling wastewater-based epidemiology with data-driven machine learning for managing public health risks.Risk analysis : an official publication of the Society for Risk Analysis · 2025Article
- Finding the MissingAntibiotics (Basel, Switzerland) · 2025Article
- Early ribavirin reduce RSV symptoms duration in post-allogeneic stem cell transplant: challenges in symptoms duration assessment.Bone marrow transplantation · 2025Article
- Changes in use of multiplex respiratory panel testing during the COVID-19 pandemic.Infection control and hospital epidemiology · 2024Observational
- FDA's proposed rule and its regulatory impact on emerging and reemerging neglected tropical diseases in the United States.PLoS neglected tropical diseases · 2024Review
- Evolving Concepts in Helicobacter pylori Management.Gastroenterology · 2024Review
- Clinical Correlation of Adenoviral Load in the Respiratory Tract Measured by Digital PCR in Immunocompromised Children.Open forum infectious diseases · 2023Article
- An assessment of the public health surveillance strategy based on molecular testing during three major pandemic waves of COVID-19 in Brazil.PLOS global public health · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
SARS-CoV-2 was identified and diagnostic methods developed at an impressive speed due in great part to the wider use of molecular methods in 2019 compared with 2002 during the SARS pandemic. The development of rapid and novel molecular diagnostic assays, leveraging of the high adaptability of molecular tests, and the integration of SARS-CoV-2 genotyping into public health, clinical, and research laboratories have been some of the successes in SARS-CoV-2 molecular testing. The main challenges are related to regulatory hurdles, supply chain constraints, and laboratory preparation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.